Mezigdomide (MEZI) Plus Dexamethasone (DEX) and Bortezomib (BORT) or Carfilzomib (CFZ) in Patients With Relapsed/Refractory Multiple Myeloma (RRMM): Results From the CC-92480-MM-002 Trial

被引：0

作者：

Oriol, Albert ^{[1
,2
]}

Sandhu, Irwindeep ^{[3
]}

Raab, Marc S. ^{[4
]}

White, Darrell ^{[5
,6
]}

LeBlanc, Richard ^{[7
]}

Raje, Noopur ^{[8
]}

Ocio, Enrique M. ^{[9
]}

Perrot, Aurore ^{[10
]}

Facon, Thierry ^{[11
]}

Rodriguez, Cesar ^{[12
]}

Waesch, Ralph ^{[13
]}

Amatangelo, Michael ^{[14
]}

Zhou, Zehua ^{[14
]}

Wang, Yue ^{[14
]}

Civardi, Tiziana ^{[15
]}

Koo, Phillip ^{[14
]}

Maciag, Paulo ^{[14
]}

Zhu, Daniel ^{[14
]}

Katz, Jessica ^{[14
]}

Richardson, Paul G. ^{[16
]}

机构：

[1] Hosp Badalona Germans Trias & Pujol, Catalan Inst Oncol, Badalona, Spain

[2] Hosp Badalona Germans Trias & Pujol, Josep Carreras Inst, Badalona, Spain

[3] Univ Alberta, Edmonton, AB, Canada

[4] Univ Klinikum Heidelberg, Heidelberg, Germany

[5] Dalhousie Univ, Halifax, NS, Canada

[6] Queen Ellizabeth II Hlth Sci Ctr, Halifax, NS, Canada

[7] Univ Montreal, Hop Maisonneuve Rosemont, Montreal, PQ, Canada

[8] Massachusetts Gen Hosp, Boston, MA USA

[9] Hosp Univ Marques de Valdecilla IDIVAL, Santander, Spain

[10] Inst Univ Canc Toulouse Oncopole, Toulouse, France

[11] Univ Lille, Ctr Hosp Univ CHU Lille, Serv Malad Sang, Lille, France

[12] Icahn Sch Med Mt Sinai, New York, NY USA

[13] Univ Freiburg, Dept Med, Med Ctr, Freiburg, Germany

[14] Bristol Myers Squibb, Princeton, NJ USA

[15] Celgene Int Sarl, Boudry, Switzerland

[16] Dana Farber Canc Inst, Boston, MA USA

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2024年 / 24卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

MM-520

引用

页码：S566 / S566

页数：1

共 50 条

[31] Updated Results from a Phase Ib Study of Isatuximab Plus Pomalidomide (Pom) and Dexamethasone (dex) in Relapsed/Refractory Multiple Myeloma (RRMM)
Richardson, Paul G.
Mikhael, Joseph
Usmani, Saad Z.
Raje, Noopur
Bensinger, William
Kanagavel, Dheepak
Gao, Lei
Ziti-Ljajic, Samira
Anderson, Kenneth C.
BLOOD, 2017, 130
[32] First-in-human phase I study of the novel CELMoD agent CC-92480 combined with dexamethasone (DEX) in patients (pts) with relapsed/refractory multiple myeloma (RRMM).
Richardson, Paul G.
Vangsted, Annette J.
Ramasamy, Karthik
Trudel, Suzanne
Martinez, Joaquin
Mateos, Maria-Victoria
Rodriguez Otero, Paula
Lonial, Sagar
Popat, Rakesh
Oriol, Albert
Karanes, Chatchada
Orlowski, Robert Z.
Berdeja, Jesus G.
Wong, Lilly
Shi, Chenyang
Lamba, Manisha
Barnett, Evelyn
Pierce, Daniel W.
Pourdehnad, Michael
Bahlis, Nizar J.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[33] Cost-effectiveness of carfilzomib plus dexamethasone compared with bortezomib plus dexamethasone for patients with relapsed or refractory multiple myeloma in the United States
Jakubowiak, Andrzej J.
Houisse, Ivan
Majer, Istvan
Benedict, Agnes
Campioni, Marco
Panjabi, Sumeet
Ailawadhi, Sikander
EXPERT REVIEW OF HEMATOLOGY, 2017, 10 (12) : 1107 - 1119
[34] A randomized, multicenter, phase (Ph) III study comparing carfilzomib (CFZ), lenalidomide (LEN), and dexamethasone (Dex) to LEN and Dex in patients (Pts) with relapsed multiple myeloma (MM).
Moreau, P.
Palumbo, A. P.
Stewart, A. K.
Rajkumar, V.
Jakubowiak, A. J.
Halka, K.
Goranov, S.
Bumbea, H.
Pendergrass, K. B.
Lupu, A.
Dimopoulos, A.
Rocafiguera, A. O.
Gandhi, J. G.
Mihaylov, G.
Masszi, T.
Matous, J.
Fonseca, G.
Bryce, R.
Siegel, D. S. D.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[35] Phase II study of lenalidomide (Len), bortezomib (Bz), and dexamethasone (Dex) in patients (pts) with relapsed or relapsed and refractory multiple myeloma (MM)
Anderson, K. C.
Jagannath, S.
Jakubowiak, A.
Lonial, S.
Raje, N.
Schlossman, R.
Munshi, N.
Knight, R.
Esseltine, D.
Richardson, P. G.
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
[36] Final results of a phase Ib study of isatuximab (ISA) plus pomalidomide (Pom) and dexamethasone (dex) in relapsed/refractory multiple myeloma (RRMM).
Mikhael, Joseph
Richardson, Paul G.
Usmani, Saad Zafar
Raje, Noopur S.
Bensinger, William
Dubin, Franck
Liu, Qianying
Vitse, Olivier
Anderson, Kenneth Carl
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[37] A randomized phase II study of bortezomib (Btz)/dexamethasone (dex) with or without elotuzumab (Elo) in patients (pts) with relapsed/refractory multiple myeloma (RRMM).
Jakubowiak, Andrzej J.
Offidani, Massimo
Pegourie, Brigitte
De La Rubia, Javier
Garderet, Laurent
Laribi, Kamel
Bosi, Alberto
Marasca, Roberto
Laubach, Jacob
Mohrbacher, Ann
Carella, Angelo Michele
Singhal, Anil K.
Tsao, Claire
Lynch, Mark John
Bleickardt, Eric W.
Jou, Ying-Ming
Palumbo, Antonio
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[38] Iberdomide in combination with dexamethasone and daratumumab or bortezomib in patients with relapsed/Refractory multiple myeloma: first results from the CC-220-MM-001 study
van de Donk, Niels W. C. J.
Popat, Rakesh
Larsen, Jeremy
Minnema, Monique C.
Jagannath, Sundar
Oriol, Albert
Zonder, Jeffrey A.
Richardson, Paul G.
Rodriguez Otero, Paula
Badros, Ashraf Z.
Stadtmauer, Edward
Bringhen, Sara
Campagnaro, Erica
Siegel, David S.
Gamberi, Barbara
Gironella Mesa, Mercedes
Sonneveld, Pieter
Tuong Vi Nguyen
Di Micco, Antonia
Sorrell, April
Chen, Min
Amatangelo, Michael
Kueenburg, Elisabeth
Lonial, Sagar
BRITISH JOURNAL OF HAEMATOLOGY, 2021, 193 : 17 - 18
[39] Phase I trial of suberoylanilide hydroxamic acid (SAHA) plus bortezomib (Bort) in relapsed multiple myeloma (MM) patients (pts).
Badros, Ashraf
Philip, S.
Niesvizky, R.
Goloubeva, O.
Harris, C.
Zweibel, J.
Wright, J.
Burger, A.
Grant, S.
Baer, M. K.
Egorin, M. J.
BLOOD, 2007, 110 (11) : 354A - 354A
[40] ANCHOR (OP-104): Melflufen plus dexamethasone (dex) and bortezomib (BTZ) in relapsed/refractory multiple myeloma (RRMM)-Optimal dose, updated efficacy and safety results.
Hajek, Roman
Pour, Ludek
Granell, Miquel
Maisnar, Vladimir
Richardson, Paul G.
Norin, Stefan
Sydvander, Malin
Obermueller, Jakob
Ocio, Enrique M.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)

← 1 2 3 4 5 →